HIK vs. HCM, INDV, AMYT, BMK, AGY, APH, BXP, ANCR, EAH, and CEL
Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Benchmark (BMK), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), ECO Animal Health Group (EAH), and Celadon Pharmaceuticals (CEL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than HUTCHMED. MarketBeat recorded 1 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.59 beat Hikma Pharmaceuticals' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.
35.4% of HUTCHMED shares are owned by institutional investors. Comparatively, 37.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 42.9% of HUTCHMED shares are owned by insiders. Comparatively, 30.6% of Hikma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
HUTCHMED has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
Hikma Pharmaceuticals received 602 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.56% of users gave Hikma Pharmaceuticals an outperform vote.
HUTCHMED has a net margin of 12.03% compared to HUTCHMED's net margin of 6.61%. Hikma Pharmaceuticals' return on equity of 14.65% beat HUTCHMED's return on equity.
Hikma Pharmaceuticals has a consensus target price of GBX 2,050, suggesting a potential upside of 3.54%. Given HUTCHMED's higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.
Summary
Hikma Pharmaceuticals beats HUTCHMED on 11 of the 17 factors compared between the two stocks.
Get Hikma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hikma Pharmaceuticals Competitors List
Related Companies and Tools
